

訂 正

Errata

Vol. 31 (2022) No. 3 「2019年JAPAN Critical Limb Ischemia Database (JCLIMB) 年次報告」にて下記内容に誤りがありました。お詫びして訂正いたします。

p. 164 Table 1-1-1 Woundを以下のとおり変更

誤：

Grade	Ulcer	Gangrene
0	No ulcer No gangrene	No gangrene
	Clinical description: ischemic rest pain (requires typical symptoms+ischemia grade 3); no wound.	
1	Small, shallow ulcer(s) on distal leg or foot; no exposed bone, unless limited to distal phalanx	No gangrene
	Clinical description: minor tissue loss. Salvageable with simple digital amputation (1 or 2 digits) or skin coverage.	
2	Deeper ulcer with exposed bone, joint or tendon; generally not involving the heel; gangrenous changes limited to digits shallow heel ulcer, without calcaneal involvement	Gangrenous changes limited to digits
	Clinical description: major tissue loss salvageable with multiple (3) digital amputations or standard TMA±skin coverage.	
3	Extensive, deep ulcer involving forefoot and/or midfoot; deep, full thickness heel ulcer±calcaneal involvement	Extensive gangrene involving forefoot and/or midfoot; full thickness heel necrosis 6 calcaneal involvement
	Clinical description: extensive tissue loss salvageable only with a complex foot reconstruction or nontraditional TMA (Chopart or Lisfranc); flap coverage or complex wound management needed for large soft tissue defect	

TMA; transmetatarsal amputation

正：

Grade	Ulcer	Gangrene
0	No ulcer	No gangrene
	Clinical description: ischemic rest pain (requires typical symptoms+ischemia grade 3); no wound.	
1	Small, shallow ulcer(s) on distal leg or foot; no exposed bone, unless limited to distal phalanx	No gangrene
	Clinical description: minor tissue loss. Salvageable with simple digital amputation (1 or 2 digits) or skin coverage.	
2	Deeper ulcer with exposed bone, joint or tendon; generally not involving the heel; gangrenous changes limited to digits shallow heel ulcer, without calcaneal involvement	Gangrenous changes limited to digits
	Clinical description: major tissue loss salvageable with multiple (3) digital amputations or standard TMA±skin coverage.	
3	Extensive, deep ulcer involving forefoot and/or midfoot; deep, full thickness heel ulcer±calcaneal involvement	Extensive gangrene involving forefoot and/or midfoot; full thickness heel necrosis 6 calcaneal involvement
	Clinical description: extensive tissue loss salvageable only with a complex foot reconstruction or nontraditional TMA (Chopart or Lisfranc); flap coverage or complex wound management needed for large soft tissue defect	

TMA; transmetatarsal amputation

p. 171 Table 3-2 下部キャプション^{*4)}を下線部のとおり変更

誤：

^{*4)} The signs of SIRS are manifested by two or more of the following: ① Temperature >38°C or <36°C, ② Heart rate >90 beats/min, ③ Respiratory rate >20 breaths/min or PaCO₂<32 mmHg, ④ White blood cell count >12000 or 4000 cu/mm or 10% immature (band) forms

正：

^{*4)} The signs of SIRS are manifested by two or more of the following: ① Temperature >38°C or <36°C, ② Heart rate >90 beats/min, ③ Respiratory rate >20 breaths/min or PaCO₂<32 mmHg, ④ White blood cell count >12000 or ≤4000 cu/mm or 10% immature (band) forms

p. 177 Table 4-5 Treatment 5を以下のとおり変更

誤：

a. Total

	Pharmacological therapy					
	Antiplatelet	Anticoagulant	Prostaglandin	Heparin	Statin	Others
Rutherford 4	96	15	1	6	14	6
Rutherford 5	289	23	23	32	56	23
Rutherford 6	66	9	7	8	9	3
Total	451	50	31	46	79	32

b. ASO

	Pharmacological therapy					
	Antiplatelet	Anticoagulant	Prostaglandin	Heparin	Statin	Others
Rutherford 4	95	15	1	6	14	5
Rutherford 5	283	30	23	32	55	20
Rutherford 6	66	9	7	8	9	3
Total	444	54	31	46	78	28

正：

a. Total

	Pharmacological therapy					
	Antiplatelet	Anticoagulant	Prostaglandin	Heparin	Statin	Others
Rutherford 4	96	15	1	6	14	6
Rutherford 5	289	31	23	32	56	23
Rutherford 6	66	9	7	8	9	3
Total	451	55	31	46	79	32

b. ASO

	Pharmacological therapy					
	Antiplatelet	Anticoagulant	Prostaglandin	Heparin	Statin	Others
Rutherford 4	95	15	1	6	14	5
Rutherford 5	283	30	23	32	55	20
Rutherford 6	66	9	7	8	9	3
Total	444	54	31	46	78	28

p. 180 Table 5-3 Perioperative complications 2を以下のとおり変更

誤：

	Hemorrhage				Site of bleeding				Outcome of bleeding				Complication due to contrast medium				Complication at puncture site			
	(-)	(+)	Unknown	Brain	GI tract	Others	Cured	Uncured	Dead	Others	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(+)
Local condition																				
Rutherford 4	124	2	1	0	2	0	2	0	0	0	127	0	68	0						
Rutherford 5	581	11	1	0	4	7	8	1	2	0	590	3	352	3						
Rutherford 6	114	5	1	0	2	3	5	0	0	0	120	0	65	1						
Therapeutic measures																				
Non-reconstruction	7	0	0	0	0	0	0	0	0	0	7	0	13	0						
EVT	415	5	1	0	2	3	5	0	0	0	419	2	417	4						
Surgical reconstruction	397	13	2	0	6	7	10	1	2	0	411	1	55	0						
Total	819	18	3	0	8	10	15	1	2	0	837	3	485	4						
b. ASO																				
	Hemorrhage				Site of bleeding				Outcome of bleeding				Complication due to contrast medium				Complication at puncture site			
	(-)	(+)	Unknown	Brain	GI tract	Others	Cured	Uncured	Dead	Others	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(+)
Local condition																				
Rutherford 4	123	2	1	0	2	0	2	0	0	0	126	0	68	0						
Rutherford 5	567	10	1	0	4	6	7	1	2	0	575	3	345	3						
Rutherford 6	112	5	1	0	2	3	5	0	0	0	118	0	65	1						
Therapeutic measures																				
Non-reconstruction	7	0	0	0	0	0	0	0	0	0	7	0	13	0						
EVT	409	5	1	0	2	3	5	0	0	0	413	2	411	4						
Surgical reconstruction	386	12	2	0	6	6	9	1	2	0	399	1	54	0						
Total	802	17	3	0	8	9	14	1	2	0	819	3	478	4						
GI; gastrointestinal, EVT; endovascular treatment																				

正：

a. Total														
	Hemorrhage			Site of bleeding			Outcome of bleeding				Complication due to contrast medium		Complication at puncture site	
	(-)	(+) (+)	Unknown	Brain	GI tract	Others	Cured	Uncured	Dead	Others	(-)	(+) (+)	(-)	(+) (+)
Local condition														
	124	2	1	0	2	0	2	0	0	0	127	0	68	0
	581	11	1	0	4	7	8	1	2	0	590	3	352	3
	114	5	1	0	2	3	5	0	0	0	120	0	65	1
Therapeutic measures														
	7	0	0	0	0	0	0	0	0	0	7	0	13	0
	415	5	1	0	2	3	5	0	0	0	419	2	417	4
	397	13	2	0	6	7	10	1	2	0	411	1	55	0
	819	18	3	0	8	10	15	1	2	0	837	3	485	4
b. ASO														
	Hemorrhage			Site of bleeding			Outcome of bleeding				Complication due to contrast medium		Complication at puncture site	
	(-)	(+) (+)	Unknown	Brain	GI tract	Others	Cured	Uncured	Dead	Others	(-)	(+) (+)	(-)	(+) (+)
Local condition														
	123	2	1	0	2	0	2	0	0	0	126	0	68	0
	567	10	1	0	4	6	7	1	2	0	575	3	345	3
	112	5	1	0	2	3	5	0	0	0	118	0	65	1
Therapeutic measures														
	7	0	0	0	0	0	0	0	0	0	7	0	13	0
	409	5	1	0	2	3	5	0	0	0	413	2	411	4
	386	12	2	0	6	6	9	1	2	0	399	1	54	0
	802	17	3	0	8	9	14	1	2	0	819	3	478	4
GI; gastrointestinal, EVT; endovascular treatment														